Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.06T | 1.06T | 967.29B | 922.42B | 755.17B | 538.13B |
Gross Profit | 887.70B | 887.70B | 802.51B | 754.73B | 621.19B | 440.88B |
EBITDA | 554.43B | 564.97B | 508.78B | 510.44B | 426.67B | 284.31B |
Net Income | 398.66B | 398.66B | 369.64B | 362.96B | 303.36B | 197.29B |
Balance Sheet | ||||||
Total Assets | 3.29T | 3.29T | 2.96T | 2.65T | 2.32T | 2.01T |
Cash, Cash Equivalents and Short-Term Investments | 1.22T | 1.22T | 1.13T | 940.46B | 1.00T | 930.00B |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Liabilities | 180.67B | 180.67B | 158.60B | 158.80B | 150.45B | 97.03B |
Stockholders Equity | 3.11T | 3.11T | 2.81T | 2.49T | 2.17T | 1.91T |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 395.18B | 375.42B | 263.28B | 265.31B | 188.29B |
Operating Cash Flow | 0.00 | 409.52B | 387.92B | 302.63B | 271.48B | 192.65B |
Investing Cash Flow | 0.00 | -280.61B | -242.79B | -283.49B | -11.13B | -177.49B |
Financing Cash Flow | 0.00 | -83.43B | -76.31B | -63.67B | -49.82B | -48.53B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $13.45T | 33.85 | 13.35% | 0.59% | 8.14% | 5.08% | |
61 Neutral | $36.03B | 6.77 | -7.27% | 2.00% | 8.65% | -7.61% | |
― | $3.49B | 36.29 | 4.46% | 3.47% | ― | ― | |
― | $29.71B | 22.45 | 8.66% | 2.21% | ― | ― | |
― | $5.14B | 23.64 | 4.20% | 2.72% | ― | ― | |
― | $7.01B | 20.60 | 10.54% | 1.74% | ― | ― | |
76 Outperform | ¥3.71T | 24.42 | 0.83% | 4.83% | -12.18% |
Keyence Corporation reported a significant increase in its consolidated financial results for the fiscal year ending March 20, 2025, with net sales rising by 9.5% and operating income by 11.1% compared to the previous year. The company also announced an increase in annual dividends per share, reflecting its strong financial performance and commitment to returning value to shareholders.